Claims

1	 A material for the diagnosis of tumors, containing a substance,
2	with which
3	- conductine of Figure 1 or parts thereof or
4	- genes, which code for conductine or parts thereof, or
5	- m-RNA sequences, which are read by these genes,
6	are detected.
1	2. The material for the diagnosis of tumors of claim 1, containing
2	specific antibodies to conductine or parts thereof.
1	3. The material for the diagnosis of tumors of claims 1 and 2, wherein
2	the specific antibodies are monoclonal antibodies.
1	4. The material for the diagnosis of tumors of claim 1, containing
2	corresponding oligonucleotide primers and/or DNA probes for the detection of the
3	genes and their mutations.
1	5. The material for the diagnosis of tumors of claim 1, containing
2	corresponding oligonucleotide primers and/or DNA probes for the detection of RNA
3	sequences.
1	6. A material for the treatment of tumors containing a substance,
2	which activates/reactivates the action of conductine in the body.
l	7. The material of claim 6, containing a substance, which activates
2	the gene promoter of conductine.

1	8. The material of claim 6, containing a substance, which increases
2	the stability of mRNA sequences.
1	9. The material of claim 6, containing a substance, which increases
2	the activity of conductine.
1	10. Conductine, characterized by the amino acid sequence 1 to 840 of
2	Figure 1 (SEQ ID No. 1), Figure 1 being part of this claim.
1	11. The partial sequence of conductine of claim 10, characterized by
2	the amino acid sequence 78 to 200 (RGS domains) of Figure 1 (SEQ ID No. 2).
1	12. The partial sequence of conductine of claim 10, characterized by
2	the amino acid sequence 343 to 396 (GSK 3b) of Figure 1 (SEQ ID No. 3).
1	13. The partial sequence of conductine of claim 10, characterized by
2	the amino acid sequence 397 to 465 (b-catenine binding domains) of Figure 1 (SEQ
3	ID No. 4).
1	14. The partial sequence of conductine of claim 10, characterized by
2	the amino acid sequence 783 to 833 (disheveled homology region) of Figure 1 (SEQ
3	ID No. 5).
1	15. The partial sequence of Adenomatosis Poliposis Coli (APC),
2	characterized by the amino acid sequences 1464 to 1604, 1516 to 1595, 1690 to
3	1778 and 1995 to 2083 as the interaction sites of RGS domains.

16. The cDNA sequence of the conductine of the nucleotide sequence 1 1 to 2825 of Figure 2 (SEQ ID No. 6), Figure 2 being a component of this claim. 2 17. The cDNA partial sequence of the conductine of the nucleotide 1 sequence 446 to 814 (RGS gene section) of Figure 2 (SEQ ID No. 7). 2 18. The cDNA partial sequence of the conductine of the nucleotide 1 sequence 1241 to 1402 (gene section of the GSK 3b-binding domains) of Figure 2 2 (SEQ No. 8). 3 19. The cDNA partial sequence of the conductine of the nucleotide 1 sequence 1403 to 1609 (gene section of the b-catenine binding domains) of Figure 2 2 (SEQ ID No. 9). 3 20. The cDNA partial sequence of the conductine of the nucleotide 1 sequence 2561 to 2713 (gene section of the disheveled homology region) of Figure 2 2 3 (SEQ ID No. 10). 21. Use of the conductine gene for the gene therapy of tumor 1 diseases, wherein a vector is constructed with the conductine gene, a gene transfer 2 subsequently takes place in the human body and, with that, the activity of the 3

conductine in the cells of the body is restored.

4